Use of maraviroc, the first CCR5 receptor antagonist, in HIV treatment regimens

Kravchenko A.V.

doi:https://doi.org/

Kravchenko A.V.

Tsentral'nyĭ NII épidemiologii Rospotrebnadzora

Use of maraviroc, the first CCR5 receptor antagonist, in HIV treatment regimens

Authors:

Kravchenko A.V.

More about the authors

Journal: Therapeutic Archive. 2013;85(11): 125‑129

Read: 1686 times

Download PDF (RU)

Contact the author

Table of contents

Как цитировать:

Kravchenko AV. Применение препарата маравирок - первого антагониста рецепторов CCR5 - в схемах терапии ВИЧ-инфекции. Терапевтический архив. 2013;85(11):125‑129. (In Russ.)

Использование инфографики авторами научных работ

Закрыть метаданные

Recommended articles:

Pregnancy and childbirth outcomes in HIV-infected women. Russian Bulletin of Obstetrician-Gynecologist. 2026;(1):18-23

HIV-associated diseases in dermatovenereologist’s practice: risk factors and stages of comorbid diagnosis formation. Russian Journal of Clinical Dermatology and Venereology. 2026;(1):72-82

Manifestation of HIV infection in the oral cavity depending on susceptibility to antiretroviral therapy. Russian Journal of Stomatology. 2026;(1):105-109

Antiretroviral therapy-associated polyneuropathy in patients with HIV infection. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(4):28-34

Резюме / Abstract:

The paper gives the results of international trials of and guidelines for the use of maraviroc, the first CCR5 receptor antagonist, in treatment regimens for HIV-infected patients. The trials have convincingly shown that the maraviroc-containing antiretroviral therapy (ART) regimens are highly effective and safe for R5-tropic HIV-infected patients regardless of previous ART, baseline HIV RNA levels, and CD4+ lymphocyte count. Maraviroc can be recommended for HIV-infected patients who have previously received ART and who have been found to have a R5-tropic virus. The changes in the ART regimen and inclusion of maraviroc may be associated with both an ineffective previous treatment regimen and therapy-induced adverse events. In 2012, Russia's first reagent kit for the determination of HIV tropism was put to tests and registered at the Russian Inspectorate for the Protection of Consumer Rights and Human Welfare.

Ключевые слова / Keywords:

HIV infection

antiretroviral therapy

CCR5 receptor antagonists

maraviroc

Авторы / Authors:

Kravchenko A.V.

Tsentral'nyĭ NII épidemiologii Rospotrebnadzora

Закрыть метаданные

Литература / References:

Briz V., Poveda E., Soriano V. HIV entry inhibitors: mechanisms of action and resistance pathways. J Antimicrob Chemother 2006; 57: 619-627.
Connor R.I., Sheridan K.E., Ceradini D. et al. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997; 185: 621-628.
Scarlatti G., Tresoldi E., Bjorndal A. et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997; 3: 1259-1265.
Fatkenheuer G., Pozniak A.L., Johnson M.A. et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005; 11: 1170-1172.
Lopatukhin A.E., Kireev D.E., Kuevda D.A. Razrabotka edinoi standartizovannoi metodiki opredeleniya tropizma VICh u patsientov pered vvedeniem v sostav ARV-terapii preparata - antagonista CCR5-retseptorov. VII Vseros. nauch.-prakt. konf. s mezhdunar. uch. "Molekulyarnaya diagnostika - 2010". Sb. tr. pod red. akad. RAMN V.I. Pokrovskogo, t. I. 2010: 59-63.
Lopatukhin A.E., Kireev D.E., Polyakov A.N. i dr. Pervyi opyt primeneniya standartizirovannoi genotipicheskoi metodiki opredeleniya tropizma VICh. Klin lab diagn 2013; 6: 46-48.
Guidelines for the Clinical Management and Treatment of HIV-infected Adults in Europe (Version 6.1; November, 2012). European AIDS Clinical Society (http://www.europeanaidsclinicalsociety.org).
Obsledovanie i antiretrovirusnaya terapiya u vzroslykh i podrostkov. Klinicheskii protokol dlya Evropeiskogo regiona VOZ (obnovlennaya versiya 2012 g.) VOZ, Kopengagen 2012; 91.
Pokrovskii V.V., Yurin O.G., Kravchenko A.V. i dr. Protokoly dispansernogo nablyudeniya i lecheniya bol'nykh VICh-infektsiei. Epidemiologiya i infektsionnye bolezni. Aktual'nye voprosy 2012, № 6 (prilozhenie).
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Developed by the Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) February 12, 2013 (http://AIDSinfo.nih.gov).
Gulick R.M., Lalezari J., Goodrich J. et al. Maraviroc for previously treated patients with R5 HIV-1 infection. New Engl J Med 2008; 359 (14): 1429-1441.
Hardy W.D., Gulick R.M., Mayer H. et al. Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2. Acquir Immune Defic Syndr 2010; 55 (5): 558-564.
Ayoub A., Alston S., Goodrich J. et al. Hepatic safety and tolerability in the maraviroc clinical development program. AIDS 2010; 24: 2743-2755.
Gulick R., Fätkenheuer G., Burnside R. et al. 5-year safety evaluation of maraviroc in HIV-1-infected, treatment-experienced patients XIX International AIDS Conference. Washington, DC, USA, July 22-27, 2012; TUPE029.
Nasta P. Maraviroc (MVC) reduces liver stiffness (LS) in HIV-hepatitis C (HCV) co-infected patients. 6th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Rome, 2011. abstract WEAB0105.
Cooper D.A., Heera J., Goodrich J. et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010; 201 (6): 803-813.
Sax P.E. Maraviroc for treatment-naive patients with HIV-1 infection: is the glass half empty or half full? J Infect Dis 2010; 201 (6): 797-799.
Vitiello P., Brudney D., MacCartney M. et al. Responses to Switching to Maraviroc-Based Antiretroviral Therapy in Treated Patients with Suppressed Plasma HIV-1-RNA Load. Intervirology 2012; 55: 172-178.
Mills A., Mildvan D., Podzamczer D. et al. Safety and immunovirological activity of once daily maraviroc (MVC) in combination with ritonavir-boosted atazanavir (ATV/r) compared to emtricitabine 200mg/tenofovir 300mg QD (TDF/FTC) + ATV/r in treatment-naïve patients infected with CCR5-tropic HIV-1 (Study A4001078): A week 24 planned interim analysis. Program and abstracts of the 17th International AIDS Conference; July 18-23, 2010; Vienna, Austria. Abstract THLBB203.
Colbers A., Best B., Wang J. et al. A Comparison of the Pharmacokinetics of Maraviroc during Pregnancy and Postpartum. 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), Atlanta, USA, 2013 Poster №931.